期刊文献+

氢吗啡酮用于患儿术后父母控制静脉镇痛的效果 被引量:7

Efficacy of hydromorphone for postoperative parent-controlled intravenous analgesia in pediatric pa-tients
原文传递
导出
摘要 目的评价氢吗啡酮用于患儿术后父母控制静脉镇痛的效果。方法择期行发育性髋关节脱位矫形术的患儿75例,性别不限,年龄2~5岁,ASA分级Ⅰ或Ⅱ级。采用随机数字表法分为2组:舒芬太尼组(S组,n=38)和氢吗啡酮组(H组,n=37)。术后48 h内进行父母控制静脉镇痛,S组配方为舒芬太尼2 μg/kg,H组配方为氢吗啡酮200 μg/kg,均加生理盐水混合至100 ml,输注速度2 ml/h,单次剂量0.5 ml,锁定时间15 min。于拔除气管导管后0.5、1、4、8、12、24和48 h(T1~7)时记录Ramsay镇静评分,于术前1 h(T0)、T3、T6时测定血清P物质浓度,记录镇痛药物消耗总量、镇痛泵有效及无效按压次数、父母满意度评分和患儿药物相关不良反应发生情况。结果与S组比较,H组T1~3时镇静评分降低,无效按压次数增多(P〈0.05),药物消耗总量、有效按压次数、父母满意度评分、血清P物质浓度和药物相关不良反应发生率差异无统计学意义(P〉0.05)。结论氢吗啡酮可安全有效地用于小儿术后父母控制静脉镇痛。 ObjectiveTo evaluate the efficacy of hydromorphone for postoperative parent-controlled intravenous analgesia in pediatric patients. MethodsSeventy-five pediatric patients of both sexes, aged 2-5 yr, of American Society of Anesthesiologists physical status ⅠorⅡ, scheduled for elective surgery for treatment of developmental displasia of the hip, were divided into 2 groups using a random number table: sufentanil group(group S, n=38)and hydromorphone group(group H, n=37). Parent-controlled intravenous analgesia was carried out within 48 h after operation.Parent-controlled intravenous analgesia solution contained sufentanil 2 μg/kg(group S)or hydromorphone 200 μg/kg(group H)in 100 ml of normal saline.The analgesia pump was set up with a 0.5 ml bolus dose, a 15-min lockout interval and infusion at a rate of 0.5 ml/h.Ramsay sedation scores were recorded at 0.5, 1, 4, 8, 12, 24 and 48 h after extubation(T1-7). At 1 h before operation(T0), T3 and T6, blood samples were collected from the ulnar vein for determination of the concentration of substance P in serum.The total consumption of analgesics, the number of successfully delivered doses, the number of attempts and drug-related adverse reactions were recorded, and parents′ satisfaction was scored. ResultsCompared with group S, Ramsay sedation scores were significantly decreased at T1-3, the number of attempts was increased(P〈0.05), and no significant change was found in the total consumption of analgesics, the number of successfully delivered doses, degree of parents′ satisfaction, serum concentration of substance P or incidence of drug-related adverse reactions in group H(P〉0.05).ConclusionHydromorphone can be safely and effectively used for postoperative parent-controlled intravenous analgesia in pediatric patients.
出处 《中华麻醉学杂志》 CSCD 北大核心 2017年第8期947-950,共4页 Chinese Journal of Anesthesiology
关键词 氢吗啡酮 镇痛 病人控制 儿童 Hydromorphone Analgesia,patient-controlled Child
  • 相关文献

参考文献3

二级参考文献48

  • 1Quigley c, wiffen P. A systematic review of hydromor- phone in acute and chronic pain. J Pain Symptom Manage, 2003, 25:169 - 178.
  • 2Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage, 2005, 29:$57 - 66.
  • 3Moore KT, St-Fleur D, Marricco NC, et al. Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study inhealthy volunteers. J Opioid Manag, 2010, 6:351 - 358.
  • 4Vandenbossche J, Richarz U, Richards HM. Repeat- dose steady-state pharmacokinetic evaluation of once- daily hydromorphone extended-release (OROS(~) hydromorphone ER) in patients with chronic pain. J Pain Res. 2012, 5:523 - 533.
  • 5Felden L, Walter C, Harder S, et al. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. Br J Anaesth, 2011,107:319-328.
  • 6Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging, 2010, 27:417 - 433.
  • 7Wright AW, Mather LE, Smith MT. Hydromorphone- 3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide.Life Sci, 2001,69:409 - 420.
  • 8Durnin C, Hind ID, Ghani SP, et al. Pharmacokinetics of oral immediate-release hydromorphone (DilaudidlR) in subjects with moderate hepatic impairment. Proc West PharmacolSoc, 2001, 44:83 - 84.
  • 9Deandrea S, Montanari M, Moja L, et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol, 2008, 19:1985 - 1991.
  • 10Hale M, Khan A, Kutch M, et al. Once-daily OROS hydromorphone ER compared with placebo in opioid- tolerant patients with chronic low back pain. Curr Med Res Opin. 2010; 26:1505 - 1518.

共引文献73

同被引文献41

引证文献7

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部